retatrutide clinical trials phase Eli Lilly's 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments retatrutide drug retatrutide clinical trials

Treatment of cells with GYY4137, an exogenous donor that releases H 2 S with slower kinetics, also inhibited both GLP-1 and PYY release (43 4% inhibition in GLP-1 release and 68 6% inhibition in PYY release with 10 mM GYY4137) (Figures 6A,B)

McClean PL, Holscher C

Discovery pharmacology was reported by Coskun and colleagues (Cell Metab, 2022), with phase 2 data published in obesity and in type 2 diabetes during 2023

Poor sleep is associated with poor glucose control, diabetes, many chronic diseases, and higher incidences of all-cause mortality

Repurposing metformin as a potential treatment for inflammatory bowel disease: evidence from cell to the clinic

Solutions and Innovations Development of Oral Formulations: Companies like Eli Lilly are focusing on oral GLP-1 drugs to improve patient adherence and convenience